QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?

CONCLUSIONS: From a regulatory perspective one cannot refute the possibility of a clinically relevant risk from QT shortening through the current testing requirements. Lack of further investigations into any potential morphological changes to the AP, or APD90 shortening beyond a specified threshold in our opinion does not fully exclude the possibility of proarrhythmic effects of active substances.PMID:35621140 | DOI:10.1080/03007995.2022.2083401
Source: Current Medical Research and Opinion - Category: Research Authors: Source Type: research